



**Mauna Kea Technologies**

**FOR IMMEDIATE RELEASE**

For further information:

Fern Lazar  
Lazar Partners  
212-867-1762  
flazar@lazarpartners.com

**Mauna Kea Announces Important Clinical and Commercial Milestones**

*- Cellvizio® Featured in Several Peer Review Publications and at Boston International Live Endoscopy Course -*

*- New Distributor Completes First Italian Commercial Installation -*

Paris, France – October 22, 2007 -- Mauna Kea Technologies (MKT), the leader in the field of in vivo cellular imaging, announced that data and images using its Cellvizio® GI imaging system have been published in a recent issue of *Clinical Gastroenterology and Hepatology*. MKT also announced that its Italian distributor, M.G. Lorenzatto, installed the first Cellvizio GI system at the Policlinico Federico II in Naples. MKT's Cellvizio® GI and Cellvizio® LUNG imaging systems enable the evaluation of suspected diseased tissue without the need for obtaining tissue biopsies.

**Growing Clinical Validation**

A case study using Cellvizio® GI was featured as the Image of the Month in the September issue of *Clinical Gastroenterology and Hepatology*. Cellvizio was utilized to visualize lymphoepithelial lesions in gastric mucosa-associated lymphoid tissue type lymphoma. The author concludes that Cellvizio GI confocal laser microscopy may have the potential to increase the accuracy of lymphoepithelial lesion diagnosis in patients suspected for gastric lymphoma.

- more-

On October 6<sup>th</sup>, The Boston International Live Endoscopy Course (BILEC) broadcast a live procedure from the Hôpital Princesse Grace in Monte Carlo where Dr. Giovannini, from Institut Paoli-Calmettes in Marseille used Cellvizio® GI to characterize and treat polyps during routine colonoscopy.

“Cellvizio® holds the promise of optimizing patient care. These data are consistent with other studies demonstrating the utility of this non-invasive imaging system in routine clinical practice,” said Sacha Loiseau, Ph.D. president and CEO of Mauna Kea Technologies. “Our goal is to continue to work with the medical community to increase the body of clinical data that demonstrate Cellvizio’s utility as a complement, and in some cases, an alternative to pathology procedures.”

The Cellvizio® GI system provides important information that can be used to monitor and diagnose disease and has the potential to target biopsy procedures,” commented Prof. Giovanni De Palma, Chief of the Endoscopy Department at the Policlinico Federico II in Naples, Italy. “Although typically uncomplicated, gastrointestinal biopsies are associated with a risk of bleeding or infection and may also allow malignant cells to migrate to other parts of the body. We are very pleased to be able to offer our patients a non-invasive method for evaluating the gastrointestinal tract.”

### **Strong Presence at the Italian Congress of Gastroenterology and Endoscopy**

Mauna Kea also announced that through its distributor, the Company had a strong presence at the annual Italian Congress of Gastroenterology and Endoscopy in Palermo September 29 - Oct.3. There was strong interest in Cellvizio by the more than 800 gastroenterologists who attended to learn more about confocal microscopy.

### **About Mauna Kea Technologies:**

Mauna Kea Technologies (MKT) engages in the conception, development, fabrication and commercialization of novel high-speed minimally invasive imaging systems for in-vivo and in-situ microscopy. MKT’s unique fiber-based microscopy platform, Cellvizio®, is the world's smallest microscope with multifarious applications in research and medicine. MKT’s products, developed at the crossroads of optics, mathematics, image processing, biology and medicine, currently address the markets of digestive endoscopy, bronchoscopy and small animal imaging. For more information, visit [www.maunakeatech.com](http://www.maunakeatech.com).

###